Security Name | Ticker | % of Net Assets |
---|---|---|
ABBVIE INC | ABBV | 6.91% |
AMGEN INC. | AMGN | 4.78% |
GILEAD SCIENCES, INC. | GILD | 4.60% |
VERTEX PHARMACEUTICALS | VRTX | 3.99% |
CORTEVA INC | CTVA | 3.59% |
ALNYLAM PHARMACEUTICALS | ALNY | 3.18% |
REGENERON PHARMACEUTICALS | REGN | 3.06% |
NATERA INC | NTRA | 2.34% |
BEONE MEDICINES LTD-ADR | BGNE | 2.34% |
ASTRAZENECA PLC ADR | AZN | 2.20% |
INSMED INC | INSM | 2.07% |
BIOGEN IDEC, INC. | BIIB | 2.04% |
ROYALTY PHARMA PLC- CL A | RPRX | 1.92% |
EXACT SCIENCES | EXAS | 1.77% |
ILLUMINA INC | ILMN | 1.77% |
NEUROCRINE BIOSCIENCES IN | NBIX | 1.74% |
EXELIXIS, INC. | EXEL | 1.67% |
UNITED THERAPEUTICS CORP | UTHR | 1.60% |
BLUEPRINT MEDICI | BPMC | 1.59% |
INCYTE CORP | INCY | 1.56% |
VIATRIS INC | VTRS | 1.52% |
BIOMARIN PHARMACEUTICAL | BMRN | 1.37% |
BRIDGEBIO PHARMA INC | BBIO | 1.32% |
GUARDANT HEALTH INC | GH | 1.31% |
ARGENX SE - ADR | ARGX | 1.30% |
REVOLUTION MEDICINES INC | RVMD | 1.29% |
BIONTECH SE-ADR | BNTX | 1.28% |
MODERNA INC | MRNA | 1.27% |
LEGEND BIOTECH CORP-ADR | LEGN | 1.22% |
IONIS PHARMACEUTICALS, IN | IONS | 1.17% |
CRISPR THERAPEUTICS AG | CRSP | 1.13% |
ALKERMES PLC | ALKS | 1.12% |
HALOZYME THERAPEUTICS INC | HALO | 1.11% |
TG THERAPEUTICS | TGTX | 1.10% |
JAZZ PHARMACEUTICALS PLC | JAZZ | 1.07% |
ROIVANT SCIENCES LTD | ROIV | 1.07% |
ADMA BIOLOGICS INC | ADMA | 1.05% |
MEDPACE HOLDINGS | MEDP | 1.00% |
AVIDITY BIOSCIENCES INC | RNA | 0.89% |
ACADIA PHARMACEUTICALS IN | ACAD | 0.89% |
AXSOME THERAPEUT | AXSM | 0.88% |
PROTAGONIST THER | PTGX | 0.86% |
CYTOKINETICS INC | CYTK | 0.83% |
SPRINGWORKS THERAPEUTICS | SWTX | 0.83% |
PTC THERAPEUTICS | PTCT | 0.82% |
ULTRAGENYX PHARM | RARE | 0.82% |
VIKING THERAPEUTICS INC | VKTX | 0.81% |
CRINETICS PHARMACEUTICALS | CRNX | 0.78% |
SUMMIT THERAPEUTICS INC | SMMT | 0.76% |
ARROWHEAD PHARMACEUTICALS | ARWR | 0.73% |
VAXCYTE INC | PCVX | 0.71% |
ASCENDIS PHA-ADR | ASND | 0.70% |
IDEAYA BIOSCIENCES INC | IDYA | 0.70% |
ARCELLX INC | ACLX | 0.69% |
AGIOS PHARMACEUT | AGIO | 0.65% |
VERACYTE INC | VCYT | 0.65% |
DENALI THERAPEUT | DNLI | 0.64% |
RECURSION PHARMACEUTICALS | RXRX | 0.64% |
NUVALENT INC-A | NUVL | 0.64% |
DYNE THERAPEUTICS INC | DYN | 0.61% |
APELLIS PHARMACE | APLS | 0.60% |
TWIST BIOSCIENCE CORP | TWST | 0.58% |
SAREPTA THERAPEU | SRPT | 0.56% |
BEAM THERAPEUTICS INC | BEAM | 0.53% |
CELLDEX THERAPEUTICS INC | CLDX | 0.53% |
AMICUS THERAPEUTICS INC | FOLD | 0.52% |
MADRIGAL PHARMAC | MDGL | 0.48% |
IMMUNOVANT INC | IMVT | 0.47% |
NOVAVAX INC | NVAX | 0.46% |
DYNAVAX TECHNOLOGY | DVAX | 0.46% |
INTELLIA THERAPE | NTLA | 0.41% |
KRYSTAL BIOTECH INC | KRYS | 0.40% |
IOVANCE BIOTHERAPEUTICS | IOVA | 0.32% |
GERON CORP | GERN | 0.29% |
Other (Cash, derivatives and other liabilities) | 0.44% | |
Total: |
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.